The annual American Society of Clinical Oncology (#ASCO17) meeting kicked off Friday, drawing a multinational gathering of more than 38,000 cancer researchers, clinicians, patient advocates, and pharmaceutical and biotechnology companies to Chicago to share the latest advances in cancer care.
As has been the case in recent years at these major cancer conferences, the emphasis has been on emerging approaches to immunotherapy, which are therapies that harness the body’s immune system to fight cancer, and precision medicine, which are therapies that target the genetic drivers of the disease. While much of the focus of this meeting is on solid tumor cancers, such as lung, breast and colon cancer, there has also been news of interest in the blood cancers.